JP2015528000A5 - - Google Patents

Download PDF

Info

Publication number
JP2015528000A5
JP2015528000A5 JP2015521769A JP2015521769A JP2015528000A5 JP 2015528000 A5 JP2015528000 A5 JP 2015528000A5 JP 2015521769 A JP2015521769 A JP 2015521769A JP 2015521769 A JP2015521769 A JP 2015521769A JP 2015528000 A5 JP2015528000 A5 JP 2015528000A5
Authority
JP
Japan
Prior art keywords
mcj
pharmaceutical composition
disease
subject
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015521769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528000A (ja
JP6442403B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/049885 external-priority patent/WO2014011742A1/en
Publication of JP2015528000A publication Critical patent/JP2015528000A/ja
Publication of JP2015528000A5 publication Critical patent/JP2015528000A5/ja
Application granted granted Critical
Publication of JP6442403B2 publication Critical patent/JP6442403B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015521769A 2012-07-11 2013-07-10 代謝調節のための方法および組成物 Active JP6442403B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261670345P 2012-07-11 2012-07-11
US61/670,345 2012-07-11
PCT/US2013/049885 WO2014011742A1 (en) 2012-07-11 2013-07-10 Method and composition for metabolic regulation

Publications (3)

Publication Number Publication Date
JP2015528000A JP2015528000A (ja) 2015-09-24
JP2015528000A5 true JP2015528000A5 (https=) 2016-08-12
JP6442403B2 JP6442403B2 (ja) 2018-12-19

Family

ID=49916526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015521769A Active JP6442403B2 (ja) 2012-07-11 2013-07-10 代謝調節のための方法および組成物

Country Status (8)

Country Link
US (3) US10583169B2 (https=)
EP (2) EP2877198A4 (https=)
JP (1) JP6442403B2 (https=)
CN (2) CN104582715A (https=)
AU (1) AU2013290266B2 (https=)
CA (1) CA2878829A1 (https=)
HK (1) HK1209650A1 (https=)
WO (1) WO2014011742A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016220024B2 (en) * 2015-02-18 2020-10-15 University Of Vermont And State Agricultural College MCJ agonists and uses therefor
WO2017011356A2 (en) * 2015-07-10 2017-01-19 University Of Vermont And State Agricultural College Methods and compositions to treat drug-induced diseases and conditions
US10694105B1 (en) * 2018-12-24 2020-06-23 Wipro Limited Method and system for handling occluded regions in image frame to generate a surround view
US20230092615A1 (en) * 2020-02-21 2023-03-23 Mitotherapeutix Llc Compositions and methods for inhibiting expressing of methylation-controlled j-protein (mcj)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5922567A (en) * 1997-06-03 1999-07-13 Incyte Pharmaceuticals, Inc. Two new human DNAJ-like proteins
US6222029B1 (en) 1997-08-01 2001-04-24 Genset 5′ ESTs for secreted proteins expressed in brain
KR100664587B1 (ko) 2004-12-22 2007-01-04 김현기 인간 암 억제 유전자, 이에 의해 코딩되는 단백질, 이를포함하는 발현 벡터 및 이 벡터로 형질전환된 세포
EP2311985A1 (en) * 2005-07-27 2011-04-20 Oncotherapy Science, Inc. Sirna for treating esophageal cancer
US20080261217A1 (en) * 2006-10-17 2008-10-23 Melnikov Anatoliy A Methylation Profile of Cancer
WO2008097467A1 (en) 2007-02-02 2008-08-14 University Of Vermont And State Agricultural College Anti-methylation-controlled j protein antibodies and uses thereof

Similar Documents

Publication Publication Date Title
Zhang et al. The SLC transporter in nutrient and metabolic sensing, regulation, and drug development
Cynober et al. The 2009 ESPEN Sir David Cuthbertson. Citrulline: a new major signaling molecule or just another player in the pharmaconutrition game?
Huang et al. The role of short-chain fatty acids in kidney injury induced by gut-derived inflammatory response
TWI735546B (zh) 使用fxr促效劑之方法
Mattick et al. Branched‐chain amino acid supplementation: impact on signaling and relevance to critical illness
KR102026342B1 (ko) 란티오닌 합성효소 c-유사 2-계 치료제
JP2011503152A5 (https=)
JP2015528000A5 (https=)
AU2014413288B2 (en) Use of composition containing iron (II) amino acid chelate in preparing drug for regulating and controlling fat metabolism
CN105407907A (zh) 尿酸值下降剂
CN103919773A (zh) 9-去甲基小檗碱在制备降血脂药物中的应用
CN119700831A (zh) 鼠李糖乳酪杆菌hpt112在制备预防和/或治疗高尿酸血症药物中的应用
Li et al. Management of hepatic encephalopathy following transjugular intrahepatic portosystemic shunts: Current strategies and future directions
Brasse-Lagnel et al. Amino acid regulation of mammalian gene expression in the intestine
JP2011105640A (ja) 気道抵抗改善剤
Lo et al. The nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester diminishes the immunomodulatory effects of parental arginine in rats with subacute peritonitis
Kim et al. Ursolic acid: a promising therapeutic agent for NAFLD via inhibition of SPP1-induced Th17 cell differentiation
Çekmen et al. The impact of L-alanyl-L-glutamine dipeptide supplemented total parenteral nutrition on clinical outcome in critically patients
US20140343149A1 (en) Method of inhibiting angiogenesis
Lee et al. Combination treatment of parenteral arginine and nitric oxide inhibitor NG-nitro-L-arginine methyl ester in rats with peritonitis
CN105801663A (zh) 一种熊果酸小檗碱偶合物的制备方法及医药用途
Babri et al. Protective effect of swimming and genistein on the expression of microRNA 132, insulin growth factor 1, and brain-derived neurotrophic factor genes, as well as spatial memory, in the hippocampus of diabetic ovariectomized rats
RU2843591C1 (ru) Применение 5-пентадецилрезорцинола для повышения доли Bifidobacterium pseudolongum в микробиоте человека
JPWO2019070024A1 (ja) 肝の線維化を伴い得るｎａｆｌｄモデル動物、その作製方法、及びそれを作製するための飼料
Frietze et al. HIF-2α induction in de novo lipogenesis in metabolic dysfunction-associated steatohepatitis is dependent on IL-21 signaling.